Crexont (IPX203) vs Levodopa/carbidopa (ND0612)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Crexont (IPX203)

Marketed by Amneal Pharmaceuticals and partners

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT03670953 · Phase 3 · completed

The study was randomized, quadruple-blind, double-dummy, and active-controlled, with 506 participants entering the randomized maintenance period and 495 contributing primary-endpoint data. The clinical primary endpoint was met: IPX203 produced a significantly greater improvement in daily “good on” time than immediate-release carbidopa-levodopa (p=0.0194).

Next expected readout: February 2027 · NCT07138560 (registry estimate)

Reported efficacy

Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): IPX203 - Double-Blind Maintenance — Baseline (Week 7): 11.67 hours/day (Standard Deviation 2.943); Change at Week 20/ET: -0.39 hours/day (Standard Deviation 2.706) vs IR CD-LD - Double -Blind Maintenance — Baseline (Week 7): 11.72 hours/day (Standard Deviation 2.759); Change at Week 20/ET: -0.97 hours/day (Standard Deviation 3.081) (met)

Result source: NCT03670953

Levodopa/carbidopa (ND0612) · Onerji

Marketed by NeuroDerm Ltd.

Phase 3 in Parkinson's Diseasesmall molecule
Partial signal

NCT02577523 · Phase 2 · completed

Participants were randomized to two ND0612 regimens, but the study was only single-blinded for outcome assessors, had no placebo or active-control arm, and was small with 19 participants per group. The clinical primary endpoint was daily OFF time; although the 24-hour regimen showed a numerically greater reduction, statistical significance for the comparison was not reported, so the result is unclear.

Reported efficacy

Change in Daily "OFF" Time (Baseline to Day 28): Change in Daily "OFF" Time (Baseline to Day 28): ND0612 Regimen 1 - 24-hr Infusion -2.8 Hours (95% CI -4.6--0.9) vs ND0612 Regimen 2 - 14-hr Infusion -1.3 Hours (95% CI -3.1-0.5) (unclear)

Result source: NCT02577523

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCrexont (IPX203)Levodopa/​carbidopa (ND0612)
OFF time, change—Not reported-2.1 vs -1.4−0.7 vs placebowk 2 · n 19NCT01883505
ON time without troublesome dyskinesia, change—Not reported—Trial running · NCT04006210
UPDRS Part III, change—Not reported—Trial running · NCT04006210
MDS-UPDRS Part II, change—Not reported—Trial running · NCT04006210

OFF time, change

Crexont (IPX203)
—Not reported
Levodopa/​carbidopa (ND0612)
-2.1 vs -1.4−0.7 vs placebowk 2 · n 19NCT01883505

ON time without troublesome dyskinesia, change

Crexont (IPX203)
—Not reported
Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210

UPDRS Part III, change

Crexont (IPX203)
—Not reported
Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210

MDS-UPDRS Part II, change

Crexont (IPX203)
—Not reported
Levodopa/​carbidopa (ND0612)
—Trial running · NCT04006210
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Crexont (IPX203): 2 of 4 rows · Levodopa/carbidopa (ND0612): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCrexont (IPX203)Levodopa/​carbidopa (ND0612)
Dropout rate
—IPX203 - Dose Conversion
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
—IPX203 - Double-Blind Maintenance
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—24-hr Infusiona
NCT02577523 · Phase 2
show 4 more results
—14-hr Infusion
NCT02577523 · Phase 2
0%Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—IPX203 - Dose Conversion
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
—IPX203 - Double-Blind Maintenance
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—24-hr Infusiona
NCT02577523 · Phase 2
show 4 more results
—14-hr Infusion
NCT02577523 · Phase 2
—Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
—Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
2%IPX203 - Dose Conversion
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
3.1%IPX203 - Double-Blind Maintenance
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
10.5%24-hr Infusiona
NCT02577523 · Phase 2
show 4 more results
10.5%14-hr Infusion
NCT02577523 · Phase 2
5.3%Period 1. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
0%Period 2. ND0612
NCT01883505 · Phase 2 · registry result, not featured evidence
0%Period 2. ND0612 + Entacapone
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
dyskinesia 6.8%
nausea 4.9%
dry mouth 4.2%
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
nausea 4.3%
anxiety 2.7%
dizziness 2.3%
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
24-hr Infusiona
infusion site nodule 57.9%
infusion site erythema 26.3%
infusion site bruising 21.1%
NCT02577523 · Phase 2
show 4 more results
14-hr Infusion
infusion site nodule 36.8%
infusion site bruising 15.8%
infusion site haemorrhage 15.8%
NCT02577523 · Phase 2
fatigue 10.5% (placebo 0%)
headache 10.5% (placebo 9.1%)
abdominal pain lower 5.3% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence
blood creatinine abnormal 12.5% (placebo 0%)
dental caries 12.5% (placebo 0%)
diarrhoea 12.5% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence
back pain 12.5% (placebo 0%)
pain in extremity 12.5% (placebo 9.1%)
abdominal pain lower 0% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Crexont (IPX203)

Good on" Time -0.39 vs -0.97 IR CD-LD per day @ 20wk
absolute change · per day
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF-time 0.29 vs 0.76 IR CD-LD per day @ 20wk
absolute change · per day
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
PGI-C 29.7% (n=256) vs 18.8% (n=250) IR CD-LD @ 20wk
responder rate · % of participants
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part III 1.1 vs 0.9 IR CD-LD score @ 20wk
absolute change · score
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Part II III 2 vs 1.8 IR CD-LD score @ 20wk
absolute change · score
Change at Week 20/ET
NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

Levodopa/carbidopa (ND0612)

OFF Time -2.8 hours @ 4wk24-hr Infusion
absolute change · hours
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-1.3 hours @ 4wk14-hr Infusion
NCT02577523 · Phase 2
Good ON" Time 3.7 hours @ 4wk24-hr Infusion
absolute change · hours
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
2.8 hours @ 4wk14-hr Infusion
NCT02577523 · Phase 2
UPDRS Part 3 Motor -19.1 score @ 4wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-10.7 score @ 4wk14-hr Infusion
NCT02577523 · Phase 2
UPDRS Part 2 ADL -2.9 score @ 4wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-1.9 score @ 4wk14-hr Infusion
NCT02577523 · Phase 2
CGI-I 52.6% (n=19) @ 0.43wk24-hr Infusion
event count · % of participants
No placebo or comparator arm
Day 3: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 10 Participants as posted
show 1 more result
47.4% (n=19) @ 0.43wk*14-hr Infusion
Day 3: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 9 Participants as posted
CGI-I 73.7% (n=19) @ 4wk24-hr Infusion
event count · % of participants
No placebo or comparator arm
Day 28: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 14 Participants as posted
show 1 more result
68.4% (n=19) @ 4wk*14-hr Infusion
Day 28: Subjects with improvements
NCT02577523 · Phase 2 · converted to % from 13 Participants as posted
PDSS-2 -4.1 score @ 3.857wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-0.8 score @ 3.857wk14-hr Infusion
NCT02577523 · Phase 2
PDQ-39 Summary Index -7.5 score @ 3.857wk24-hr Infusion
absolute change · score
No placebo or comparator arm
NCT02577523 · Phase 2
show 1 more result
-3.7 score @ 3.857wk14-hr Infusion
NCT02577523 · Phase 2
OFF Time -2.1 vs -1.4 placebo hours @ 2wk
absolute change · hours
NCT01883505 · Phase 2 · registry result, not featured evidence
UPDRS Total -11.7 vs -9.3 placebo score @ 2wk
absolute change · score
NCT01883505 · Phase 2 · registry result, not featured evidence
PDSS -17.1 vs -0.5 placebo score @ 2wk
absolute change · score
NCT01883505 · Phase 2 · registry result, not featured evidence
PDQ-39 -6.6 vs -1.8 placebo score @ 2wk
absolute change · score
NCT01883505 · Phase 2 · registry result, not featured evidence

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Crexont (IPX203)'s landscape · Levodopa/carbidopa (ND0612)'s landscape